DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
Next Generation Drug Conjugates Market · GlobeNewswire Inc. Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Next Generation ...
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from ...
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...
Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody attached to a cytotoxic drug via a chemical linker. The antibody is able to identify biomarkers on and attach to cancer ...
MedPage Today on MSN
Blockbuster drug gets breast cancer approvals in curative setting
New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...
Antibody-drug conjugates (ADCs) link cancer drug payloads, such as tubulin inhibitors and DNA damaging agents, to monoclonal antibodies that selectively target tumor cells. Pernille Hemmingsen, PhD, ...
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...
Researchers use new antibody–drug conjugates that combine a CD4 mimic with neutralizing antibodies to inhibit human immunodeficiency virus (HIV) entry into host cells. New antibody–drug conjugates ...
A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results